Prazertx
1 known investors
Prazer Therapeutics develops therapeutics using Targeted Protein Degradation (TPD) technology, including its SPiDEM platform, in which small molecules selectively bind pathological proteins and activate the ubiquitin-proteasome system for their elimination. The company's pipeline focuses on treatments for viral infections and associated diseases as well as other refractory conditions.
BiotechDeep Tech
Investors · 1
Frequently asked questions
- What does Prazertx do?
- Prazer Therapeutics develops therapeutics using Targeted Protein Degradation (TPD) technology, including its SPiDEM platform, in which small molecules selectively bind pathological proteins and activate the ubiquitin-proteasome system for their elimination. The company's pipeline focuses on treatments for viral infections and associated diseases as well as other refractory conditions.
- Who are Prazertx's investors?
- Prazertx's investors include Kiwoom Investment.